



Andreas Wildi

Dr. med. et lic. iur. HSG, Avvocato
Partner
Telefono +41 58 658 29 15
andreas.wildi@walderwyss.com



Andreas Wildi, born in 1972, is a medical doctor and an attorney at law. He consults and represents Dow Jones and Nasdaq listed multinational companies as well as mid- and small cap enterprises in the Life Sciences sector. He mainly focuses on Swiss and international reimbursement & pricing law of pharmaceuticals and other therapeutic products. Regulatory issues of pharmaceuticals, medical devices, special nutrition, cosmetics, genetic testing, stem cell- and blood products are his further key areas of practise.

Andreas Wildi studied medicine at the University of Zurich and graduated as medical doctor (MD). Working part-time in hospital, GP-practice and on international rescue missions, he completed his law degree at the University of St. Gallen HSG (MLaw). Before passing the bar exam, he gained his first professional legal experience as clerk with the Cantonal Court of Schaffhausen and with a recognised business law firm in Zurich. From his first position as an attorney at law in a large Zurich business law firm, Andreas Wildi was asked to work for the Swiss Government, where he led the pharmaceutical reimbursement & pricing unit in the Federal Office of Public Health. Thereafter, Andreas Wildi broadened his market access expertise internationally, as EMEA market access law director for Janssen Pharmaceuticals (Johnson & Johnson). Since 2012, he has built up his legal practise in a large, well accepted Zurich business law firm. In 2015, Walder Wyss elected Andreas Wildi as their partner.

Andreas Wildi works in German, French and English. He is admitted to all Swiss Courts and guest lecturer on pharmaceutical law at the University of Lucerne's Faculty of Law.

Publicazioni (selezione)

Pharmaceutical Advertising 2022 – Switzerland

di Andreas Wildi e Celine Weber
in: Chambers Global Practice Guide,
2022

Kommentar zu Art. 5, 6 und 7a HMG

[Commentary on Art. 5, 6 und 7a HMG]
di Michael Isler [Co-autore], Andreas
Wildi [Co-autore] e Stephanie Eggimann
[Co-autore]
in: Eichenberger/Jaisli/Richli (Editore),
"Basler Kommentar zum
Heilmittelgesetz"
2, Basel, 2021

Entry into force of the revised Swiss Medical Devices Ordinance and its implications for the medtech industry

[Entrata in vigore della nuova ordinanza
svizzera sui dispositivi medici e le sue
implicazioni per l'industria medtech]
di Andreas Wildi e Monja Sieber
maggio 2021

The Life Sciences Law Review Chapter 24 - Switzerland

[The Life Sciences Law Review Capitolo
24 - Svizzera]
di Celine Weber e Andreas Wildi
in: The Life Sciences Law Review - 9th
Edition, Pag. 377 - 389, maggio 2021

Pharmaceutical Advertising – Switzerland

[Pubblicità farmaceutica – Svizzera]
di Andreas Wildi e Celine Weber
in: Chambers Global Practice Guide, 19
marzo 2021

**Liberté de choix de la thérapie vs
principe du caractère économique dans
le domaine de la liste des spécialités**
di Andreas Wildi, Daniel Staffelbach e
Stephanie Eggimann
novembre 2020

Therapiewahlfreiheit vs. Wirtschaftlichkeitsgebot im Bereich der Spezialitätenliste

di Andreas Wildi, Daniel Staffelbach e
Stephanie Eggimann
novembre 2020

L'elenco completo delle pubblicazioni
è disponibile su:

www.walderwyss.com/andreas.wildi